Wednesday, February 27, 2019

Best Energy Stocks To Own Right Now

tags:AMBA,MGI,PSTI,

Shares of Peabody Energy Co. (NYSE:BTU) have received an average rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $46.29.

BTU has been the topic of several research analyst reports. ValuEngine cut Peabody Energy from a “hold” rating to a “sell” rating in a research report on Thursday, August 2nd. Zacks Investment Research raised Peabody Energy from a “hold” rating to a “strong-buy” rating and set a $54.00 price objective on the stock in a research report on Friday, June 8th. MKM Partners reissued a “buy” rating and issued a $53.00 price objective on shares of Peabody Energy in a research report on Wednesday, June 6th. Finally, B. Riley boosted their price objective on Peabody Energy from $51.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday, July 25th.

Best Energy Stocks To Own Right Now: Ambarella, Inc.(AMBA)

Advisors' Opinion:
  • [By Motley Fool Transcribing]

    Ambarella (NASDAQ:AMBA) Q2 2019 Earnings Conference CallAug. 30, 2018 4:30 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator 

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Ambarella (AMBA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Ambarella (NASDAQ:AMBA) and Cypress Semiconductor (NASDAQ:CY) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

  • [By Harsh Chauhan]

    Investors' enthusiasm for Ambarella (NASDAQ:AMBA) came crashing down after the video-processing-chip specialist's fiscal first-quarter performance didn't do much to dispel fears that it was finding it difficult to grow despite operating in verticals that promise a lot of opportunities.

Best Energy Stocks To Own Right Now: Moneygram International, Inc.(MGI)

Advisors' Opinion:
  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Moneygram International (MGI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Moneygram International (MGI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    Cramer was bearish on Xilinx (XLNX) , Celgene (CELG) , Exelixis (EXEL) , Moneygram (MGI) , Monster Beverage (MNST) , SunCoke Energy Partners (SXCP) and Mattel (MAT) .

  • [By Stephan Byrd]

    Cardtronics (NASDAQ: MGI) and Moneygram International (NASDAQ:MGI) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

  • [By Max Byerly]

    BidaskClub downgraded shares of Moneygram International (NASDAQ:MGI) from a sell rating to a strong sell rating in a report issued on Thursday.

    Several other brokerages also recently commented on MGI. Zacks Investment Research downgraded shares of Moneygram International from a buy rating to a sell rating in a report on Monday, May 14th. ValuEngine downgraded shares of Moneygram International from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Finally, TheStreet downgraded shares of Moneygram International from a c rating to a d+ rating in a report on Friday, March 16th. Four analysts have rated the stock with a sell rating and one has issued a hold rating to the stock. Moneygram International has an average rating of Sell and a consensus target price of $9.75.

  • [By Motley Fool Transcribing]

    MoneyGram International (NASDAQ:MGI) Q4 2018 Earnings Conference CallFeb. 11, 2019 4:30 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator 

Best Energy Stocks To Own Right Now: Pluristem Therapeutics Inc.(PSTI)

Advisors' Opinion:
  • [By Stephan Byrd]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Pluristem Therapeutics alerts: Pluristem Therapeutics Inc. (PSTI) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com) Head-To-Head Analysis: Pluristem Therapeutics (PSTI) & Amgen (AMGN) (americanbankingnews.com) Pre-Eclampsia Treatment Market Outlook 2025, Global Opportunity & Growth Analysis, Key Players – Alnylam … (menafn.com) Flickering Three Stocks: Golden Star Resources Ltd. (NYSE:GSS), Pluristem Therapeutics Inc. (NASDAQ:PSTI … (thestreetpoint.com) Pluristem Therapeutics Inc. (PSTI) moves -0.72% higher to SMA-50 (nasdaqplace.com)

    Pluristem Therapeutics stock traded up $0.01 during trading hours on Monday, reaching $1.37. The stock had a trading volume of 3,754 shares, compared to its average volume of 201,217. The firm has a market cap of $150.78 million, a PE ratio of -4.28 and a beta of 0.32. Pluristem Therapeutics has a 52 week low of $1.12 and a 52 week high of $2.12.

  • [By Ethan Ryder]

    Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) have earned an average recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $4.13.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

No comments:

Post a Comment